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Abstract
Controlling energy homeostasis involves modulating the desire to eat and regulating energy expenditure. The controlling machinery
includes a complex interplay of hormones secreted at various peripheral endocrine endpoints, such as the gastrointestinal tract, the adi-
pose tissue, thyroid gland and thyroid hormone-exporting organs, the ovary and the pancreas, and, last but not least, the brain itself. The
peripheral hormones that are the focus of the present review (ghrelin, leptin, thyroid hormones, oestrogen and insulin) play integrated
regulatory roles in and provide feedback information on the nutritional and energetic status of the body. As peripheral signals, these hor-
mones modulate central pathways in the brain, including the hypothalamus, to influence food intake, energy expenditure and to maintain
energy homeostasis. Since the growth of the literature on the role of various hormones in the regulation of energy homeostasis shows a
remarkable and dynamic expansion, it is now becoming increasingly difficult to understand the individual and interactive roles of hormo-
nal mechanisms in their true complexity. Therefore, our goal is to review, in the context of general physiology, the roles of the five best-
known peripheral trophic hormones (ghrelin, leptin, thyroid hormones, oestrogen and insulin, respectively) and discuss their interactions
in the hypothalamic regulation of food intake.
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Introduction
The goal of the present review is to present an overview of
the most studied hormonal factors that contribute to the
central regulation of food intake and energy homeostasis
which simultaneously provide peripheral feedback signals
to the relevant hypothalamic feedback mechanisms. The
most important hormones playing such dual roles are ghre-
lin, leptin, thyroid hormones, insulin and oestrogen. Of
course, in addition to the listed hormones there are several
other humoral factors, such as catecholamines, etc, contri-
buting directly or indirectly to the regulation of energy
metabolism; however, attempts to cover all contributions
are beyond the scope of the present overview. The listed
factors highly influence the appetitive trigger that stimu-
lates food-seeking behaviour, ingestion and energy
expenditure, thereby establishing a dynamic and plastic
information channel between central, mostly hypothala-
mic, circuits and peripheral tissues. In the present search
for the blueprint of the complex regulatory machinery,
the hypothesis is that the functions of the hormones dis-
cussed in the present review cannot be understood and
may be misleading if examined in isolated environments
(i.e. singled out from the complex pool of the regulatory
circuit). They can only function appropriately when
acting together and adequate hormone interactions take
place. Thus, we will compare and review the literature
on the individual roles of the selected hormones with
those observed under the influence of one or more of
these hormones present in the actual context examined
or discussed. We believe that comparison of individual
and combined hormone effects will highlight the short-
comings of classical experimental protocols operating on
the basis of only one variable and then interpreting the
resulting data as lone-standing constituents of a more com-
plex mechanism. In fact, we believe that this comprehen-
sive review underscores that physiologically relevant data
can only be obtained from complex biological systems,
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and clinical application of experimental results should
be designed on the basis of the complex interplay of the
biological factors involved.
To best illustrate their individual and combined roles,
each of the factors will be discussed separately, then in
combination based on the available literature. Considering
that we are reviewing an enormous field of research, we
will keep the main stream of discussion within the bound-
aries of general physiology. However, we will use com-
parative animal physiology or specify sex differences
where the examples provide clarity and reveal their com-
plexity for the discussion of feedback loops or mechanisms
in the regulation of metabolic homeostasis.
General physiological roles of ghrelin, leptin, thyroid
hormones, oestrogen and insulin
Ghrelin
Ghrelin is an acylated twenty-eight-amino acid orexigenic
peptide hormone first isolated from rat stomach by
Kojima et al.(1). Ghrelin serum concentrations are below
detectable levels during fetal life but rise sharply during
the second to third postnatal weeks(2). Significant ghrelin
production has been observed in the human and rat pla-
centa(3). The X/A-like secretory cells in the oxyntic
glands of the stomach are responsible for most of the cir-
culating levels of ghrelin(1), although the hypothalamus,
hypophysis, kidney and the intestines also contribute to
ghrelin production. A high degree of ghrelin expression
was detected in several types of tumours, particularly the
adrenocorticotroph hormone-secreting thymus tumours,
gastrinomas, insulinomas, and in human pituitary carci-
nomas(4,5). Plasma levels of ghrelin are reduced by about
80 % after gastrectomy or fundectomy(6), indicating that
most ghrelin is produced by the oxyntic glands of the
stomach.
Besides its role in the regulation of neural circuits that
underly appetitive behaviour, feeding(7–9), digestion(10–12)
and thermogenesis(13), ghrelin modulates a number of
additional physiological processes that, overall, may
affect energy homeostasis, such as growth hormone
production(7,10,14), cell proliferation(9,15,16), apoptosis(9),
sleep–wake behaviour(17) and cardiovascular func-
tions(12,18,19). In addition, ghrelin receptors are found on
neurons in the arcuate nucleus of the hypothalamus
where appetite-stimulating neuropeptide Y (NPY) and
agouti-related protein (AgRP) are co-expressed(13,20),
within the hypothalamus, pituitary, small and large intes-
tines, placenta, kidney, testes, ovary and lymphocytes
and on insulin-secreting b-cells in a dose-dependent
manner(11,12,21).
Intracerebroventricular or peripheral (intravenous)
application of ghrelin stimulates food intake (appe-
tite)(22,23). Studies by several groups have demonstrated
that ghrelin supports lipogenesis and suppresses fat pad
degradation(24,25), increasing body weight and adiposity,
and leading to obesity. However, skeletal mass or bone
growth remains unaffected(24,25). Thus, ghrelin accelerates
the maturation and growth of adipocites in vitro, but
may not augment adipocyte differentiation in vivo (26,27).
Although ghrelin is an energy-deficit signal, ghrelin-null
or growth hormone secretagogue receptor (GHS-R)-null
mice do not display deficiencies in skeletal growth, body
composition and food intake(28,29). On high-fat diets,
these knock-out animals usually do not become obese
and/or insulin resistant(30,31).
The major stimulus in ghrelin secretion is fasting(32). All
parameters, including the pulse amplitude of ghrelin
release, are augmented by fasting(33). Circulating levels of
ghrelin increase after fasting and revert after feeding.
However, while a relatively short, 24 h fasting increases
serum ghrelin levels, a longer period of food restriction
does not affect postprandial ghrelin concentrations(34,35),
suggesting that ghrelin levels reflect short-term energy
deficits and corroborate a positive energy balance. The
preprandial rise of ghrelin’s plasma level in obese animals
is slower and delayed compared with those animals of
normal weight(36,37). While programmed feeding allows
for the observation of marked changes in plasma ghrelin
levels, under ad libitum feeding, ghrelin (as well as
leptin) secretion shows a pulsatile rhythm or pattern,
with a peak every 30 min on average. Ghrelin release is
not influenced by simple expansion (mechanical disten-
tion) of the stomach, but depends on the ingredients of
the meal(37–39), thus indicating that the energy content of
the meal may be a determining factor(40).
In rodents and humans, ghrelin plasma concentrations
follow changes in body weight and adiposity, but show
no alterations in circulating levels in ageing rats and
mice. Likewise, no alterations were found in ghrelin recep-
tor expression in the pituitary gland and brain of ageing
mice(41,42). Ghrelin binds to HDL, decreasing their ability
to bind and carry lipid molecules(43), inhibiting lipid
export from responsive tissue. A circadian rhythm in the
fluctuation of plasma ghrelin levels exists in rodents, with
the highest concentrations of circulating ghrelin occurring
before the dark period(44) and after waking/just before
breakfast in humans(45). Gastric ghrelin secretion increases
in the dark period. In contrast, daytime hypophyseal ghre-
lin release seems to be higher compared with night-time
values. The biodegradation of ghrelin has an important
role in the adjustment of plasma ghrelin levels. Tissue
esterases and proteases are the key enzymes in the inacti-
vation and biodegradation of ghrelin in the plasma.
The hypothalamic arcuate nucleus is a principlal target
of ghrelin. Ghrelin receptors are found on neurons in the
arcuate nucleus of the hypothalamus where NPY and
AgRP are co-expressed(13,20). Distinct populations of neur-
ons were identified in the arcuate nucleus as major players
in the regulation of food intake, such as NPY- and AgRP-
containing neurons(46) responsible for orexigenic effects

















(hunger cells), and the melanocyte-stimulating hormone/
pro-opiomelanocortin (a-MSH/POMC) satiety cells and
cocaine- and amphetamine-regulated transcript (CART)-
producing neurons responsible for anorexigenic
mechanisms. Hewson et al.(47) suggest that ghrelin exerts
its stimulatory effect on appetite and food intake/feeding
activity by stimulating NPY release. Intracerebroventricular
administration of anti-NPY IgG suppresses ghrelin’s (appe-
tite-stimulating) action, although anti-AgRP IgG had the
same effect. Nakazato et al.(24) also describe ghrelin’s
enhancing effect on AgRP and NPY mRNA levels
but found no modification of the influence of NPY/AgRP
neurons on energy expenditure.
In concert with these findings, immunohistochemical
analyses show a direct connection between NPY/AgRP
neurons and ghrelin-containing fibres(48). According to
Andrews et al.(49), ghrelin seems to act on NPY/AgRP neur-
ons by inducing mitochondrial respiration of these cells,
most probably by influencing mitochondrial proliferation
and activity of NPY/AgRP neurons via affecting uncoupling
protein (UCP) 2.
Some diseases and disorders are marked by altered ghre-
lin secretion. Prader–Willi syndrome (a genetic disorder
characterised by mental retardation, hyperphagia, short
stature and muscular hypothonia) presents with higher
plasma ghrelin concentrations(50–52), a possible factor for
the hyperphagic symptom of the disease. Anorexia nervosa
is also characterised by a high ghrelin plasma concen-
tration(53,54) which returns to a normal level after recovery
and weight gain(55). Patients suffering from short-bowel
syndrome have lower plasma ghrelin levels, supposedly
due to the missing ghrelin-producing tissues(56). The
same is observed after gastric bypass surgery(57), since
ghrelin is predominantly produced in the stomach.
Since more than 90 % of ghrelin is produced by the
stomach and duodenum, parts of the gastrointestinal tract
affected by gastric bypass surgery, a significant decrease
in ghrelin level was observed in most patients who under-
went this operation(58–60). Indeed, one of the mechanisms
by which gastric bypass reduces body weight is suppres-
sion of ghrelin production. However, the effects of
bypass surgery are much more complex and are not fully
understood. There are several other sources reporting
that there were no alterations in ghrelin levels after gastric
bypass or gastric banding(61). This discrepancy in post-
surgical ghrelin levels may be due to the difference in
surgical techniques involving, for example, treatment of
the vagus nerve(62).
Ghrelin appears to be evolutionarily conserved, as it
has been found in birds, reptiles, amphibians and fish,
although its effects may have served different functions
in specific species. In mammals, it is the only gut-derived
hormone that stimulates food intake, while in chickens, it
has the contradistinct effect of inhibition of feeding(63,64).
Ghrelin’s functions in other bird species are still unknown,
albeit energy balance and thermogenesis may be regulated
by ghrelin there as well. Nevertheless, the mechanism
is different from that of mammals and is yet to be
determined.
Leptin
Leptin is anorexigenic, inhibits excessive deposition of
lipids in various tissues and enables the organism to
adapt to periods of food deprivation or undernutrition(65).
The name ‘leptin’ is derived from the Greek word leptos,
meaning ‘thin’. Leptin is a member of the cytokine family
of peptide hormones first identified as a 16 kDa protein
secreted by the adipose tissue to regulate feeding beha-
viour and energy balance(66,67). The gene encoding for
leptin is identical to the ob gene, discovered in 1995 by
Geffroy et al.(68) as the factor responsible for obesity
when mutated. Hence, the gene was called ‘ob’, abbre-
viated from the word ‘obesity’. Geffroy et al. localised the
leptin’s ob gene to the 7th chromosome. Initial evidence
correlated levels of serum leptin with adipose tissue
mass, suggesting that it was produced by the adipose
tissue itself(69). Higher levels of ob mRNA are expressed
in the fat of obese population samples compared with
thin controls, and leptin release correlates with the size
of adipocytes, i.e. larger cells produce proportionally
higher quantities of leptin due to accumulation of
TAG(70,71). Leptin is produced predominantly, but not
exclusively, by white adipose tissue(72). It is also released
by brown adipose tissue, placenta (syncytiotrophoblasts),
ovary, skeletal muscle, stomach (epithelial cells in the
lower part of fundic glands), mammary epithelial cells,
heart, bone marrow, pituitary and the liver (especially in
birds)(73). In these organs and tissues, leptin acts as a para-
crine or autocrine hormone(65,74,75).
In an early experiment, mouse ob protein (leptin) was
purified and administered in small doses both centrally
and peripherally to genetically obese (ob/ob) mice, diet-
induced obese mice and diabetic (db/db) obese mice.
Leptin reduced food intake and body weight in both
genetically obese and diet-induced obese mice, but had
no effect on db/db obese animals. The behavioural effects
after central (intracerebral) administration suggested that
leptin acted directly on the neuronal networks that control
feeding and energy balance(76). To summarise, it was pro-
posed that the ob gene encoded the ob protein (leptin) that
regulated food intake and energy balance, and that the
extreme obesity of the genetically obese (ob/ob) mice
was attributable to mutations in the ob gene. It was also
suggested that the db gene encoded the receptors for this
factor and the extreme obesity of diabetic (db/db) mice
was attributed to mutations in the db gene(77). In another
human study on two severely obese children, serum
leptin levels were very low despite the markedly elevated
fat mass. In both children, a mutation in the leptin gene
was found, providing further evidence to support the
role of the ob gene in the regulation of leptin levels(78).

















Leptin receptor (Ob-R) is coded by the db gene. Cloning
of the mouse db gene revealed that it encodes five
alternative isoforms (a–e). All isoforms possess identical
ligand-binding domains (extracellular), but differ in their
C-terminus (intracellular), with Ob-Rb as the only isoform
able to activate the correct signal transduction pathway(79).
A further experiment showed that the mutant genotype
db/db lacks Ob-Rb, and the phenotype of the affected
mice was identical to that of genetically obese (ob/ob)
mice, characterised by obesity and diabetes (from which
the name of the gene, db, is derived)(80). Expression of
the other receptor isoforms (Ob-Ra, Ob-Rc, Ob-Rd and
Ob-Re) remained unaffected, leading to the conclusion
that, of the known receptor isoforms, only the Ob-Rb recep-
tor is essential for leptin’s weight-regulating effects(81).
Using in situ hybridisation, Ob-Rb receptors were
detected in high levels in hypothalamic neurons and hypo-
physeal cells, suggesting that these anatomical regions are
crucial sites of leptin’s actions(82). This is supported by evi-
dence that a single intracerebroventricular injection of
leptin reduces food intake at doses with no measurable
effect when delivered peripherally(83). In addition to the
central nervous system, relatively high Ob-Rb mRNA
expression levels were detected in the adipose tissue, skel-
etal muscle and liver, suggesting that leptin is likely to play
a role in peripheral lipid metabolism as well(84,85).
The transport mechanisms of leptin through the blood–
brain barrier is still undefined, but it has been hypothesised
that the receptor Ob-Ra could be involved in an active
transport mechanism in certain Ob-Rb-containing neurons
that actually project to neurohaemal brain regions (i.e. cir-
cumventricular organs) and thus avoid the blood–brain
barrier(86).
In the hypothalamus, the lateral hypothalamic and
ventromedial nuclei project both within and outside the
hypothalamus and modulate the activity of the parasympa-
thetic and sympathetic nervous systems, two overlapping
and redundant mechanisms of the central nervous system
that depend upon fight-or-flight or homeostatic demands
of the organism(87–89). The dorsomedial hypothalamic
nucleus, via its direct anatomical connections with the
parasympathetic nervous system, may be involved in inte-
grating information between the lateral hypothalamic,
ventromedial and paraventricular nuclei. The paraventric-
ular nucleus controls secretion of peptides from both the
posterior and anterior pituitary and projects to nuclei
with sympathetic or parasympathetic efferents(86,90,91).
Leptin’s central effects on the regulation of food intake
and energy metabolism are not confined to a single mech-
anism of action. Besides its direct effects on relevant neural
circuits, indirect mechanisms of leptin actions are also
known. In general, leptin down-regulates orexigenic pep-
tides, and up-regulates anorexigenic peptides, leading to
a reduction in food intake. However, there is a dynamic
and interactive effect between orexigenic and anorexigenic
factors. For example, a-MSH agonists decrease food intake,
while a-MSH antagonists act in the opposite manner to
reduce the anorexigenic effect of leptin(92). On the other
hand, peripheral and central effects of leptin can merge
to shape the final biological outcome: by the facilitation
of lipolysis in the adipose tissue, leptin increases
the plasma level of NEFA, the latter which influence
the function of relevant hypothalamic neurons, while
leptin also acts directly on hypothalamic orexigenic
neurons. Additionally, leptin up-regulates uncoupling in
UCP-expressing hypothalamic neurons and probably
other cells as well, thereby propelling energy metab-
olism/utilisation/use of energy. Therefore, along with its
stimulatory effect on sympathetic tone, leptin’s overall
effects also include increased heat production(93). In
addition to these central actions, leptin exerts considerable
peripheral effects that can be considered upstream signals
of extended hypothalamic leptin effects. In short, leptin
decreases the levels of insulin and glucocorticoids,
enhances the secretion of growth hormone, catechol-
amines and the thyroid hormones, thus stimulating
energy expenditure and hepatic lipogenesis(65). Leptin
augments mitochondrial fatty acid oxidation especially
in hepatocytes and skeletal muscle cells(94,95) and
increases insulin sensitivity and glucose metabolism in
myocytes(65,96). NPY/AgRP neurons are major targets of
leptin in the hypothalamus(97,98). In these cells, the two
antagonistic hormones, ghrelin and leptin, act in opposite
ways to modulate neuronal activity and influence food
intake, as discussed below.
Thyroid hormones
Traditionally, the hormone products of the thyroid gland
have been known as ‘thyroid hormones’. Today, the
source and function of these hormones comprise a large
body of knowledge, allowing for a remarkably complex
view on the physiological roles of thyroid hormones.
This brief summary is confined to those salient thyroid hor-
mone effects that, in one way or another, are involved in
the hypothalamic regulation of food intake.
There are various types of thyroid hormones: thyroxine
(T4), containing four iodine atoms, is generally considered
to be a prohormone, while triiodothyronine (T3), contain-
ing three iodine atoms, is biologically more active than T4.
These two hormones are inactivated by conversion to
reverse triiodothyronine (rT3) or diiodothyronine (T2).
Thyroid hormones are crucial for the maintenance of
energy equilibrium of the body: thyroid hormones regulate
the rate of metabolic processes (including the BMR),
increase O2 consumption and heat production. Conse-
quently, thyroid hormones are equally necessary for
normal reproduction, growth and development(99).
In humans, most (80 %) of the circulating T3 originates
from the periphery (i.e. not from the thyroid gland),
where T4 is converted into T3 by the corresponding
deiodinase enzymes. The most important peripheral

















T3-producing organs are the liver, kidney and the skeletal
muscle(100). In rats, more T3 is produced in the thyroid
gland (55 %) than in other peripheral tissues(101), while in
birds almost all (99 %) T3 is synthesised in peripheral tis-
sues, outside of the thyroid gland(102).
The function of the thyroid gland is regulated by a nega-
tive feedback mechanism. The hypothalamic nuclei pro-
duce thyrotropin-releasing hormone that stimulates the
adenohypophysis to produce and secrete thyroid-stimulat-
ing hormone (TSH). TSH increases T4 production in the
thyroid gland. An increase of plasma T4 concentration, in
turn, down-regulates the production of thyrotropin-releas-
ing hormone, TSH, and T4 as well
(103).
The peripheral T4-to-T3 conversion is catalysed by deio-
dinase enzymes(104). There are three types of deiodinases
in different tissues: type I deiodinase (D1), type II deiodi-
nase (D2) and type III deiodinase (D3). D1 is expressed
in the central nervous system, especially the pituitary, in
rats but not in humans(105–107). Of the lower vertebrates,
the fish brain was found to contain D1(108).
D2 expression was described in the brain (including the
pineal gland) and pituitary of rats(106) mainly as a glial
enzyme most abundant in astrocytes and tanycytes (near
the mediobasal hypothalamus)(109,110). In humans, D2 is
the only thyroid hormone-activating 50 deiodinase in the
brain(105).
D3 is ubiquitously expressed in the adult rat brain,
especially in the forebrain, cerebral cortex, pyramidal
cells of the hippocampus, granule cells of the dentate
gyrus, and in the piriform cortex(111). These brain regions
are the richest in thyroid hormone receptors(112). In neo-
natal rat brain, D3 expression is age dependent(113). In con-
trast to D2, D3 can be found mostly in neural cells(111).
D1 and D2 activate (when pH , 7, D1 may also inacti-
vate), while D3 inactivates, thyroid hormone. In mammals,
the bulk production of T3 is mediated by D1. D1 is
expressed in the liver, kidneys, thyroid gland, skeletal
muscles, lung, and in the hypophysis(114–118). In mammals,
hepatic and kidney-derived D1 is the most important
source of T3. These organs produce T3 and release it into
the bloodstream. Therefore, these are called hormone-
exporting organs(116,117,119). D2 is also expressed in the
liver in birds but not in mammals(102).
Peripheral tissues can adjust the ratio of active and inac-
tive thyroid hormones, according to their actual energy
needs and energy supply through their deiodinase activity.
Therefore, the peripheral tissues can become more or less
independent from the central regulatory processes. In the
case of appropriate energy supply, the body primarily
needs T3, thereby turning on thyroid hormone-activating
deiodination(117,119,120).
Thyroid hormones act through binding to their cognate
receptors (thyroid hormone receptors). Thyroid hormone
receptors are nuclear receptors that can stimulate ligand-
dependent transcription of certain genes(121,122). In mam-
mals, there are four thyroid hormone receptor isoforms,
thyroid hormone receptor a (TRa) 1–2 and thyroid hor-
mone receptor b (TRb) 1–2, encoded by two highly con-
served genes (Thra and Thrb, respectively)(123,124). TRa2
has not been found in non-mammalian species(125).
Unlike the other thyroid hormone receptors, TRa2 acts as
a weak repressor instead of functioning as a receptor of
T3
(126). Thyroid hormone receptors have both T3-depen-
dent and -independent functions. Interestingly, T3 can con-
vert a T3-independent repressor into a T3-dependent
activator(127).
The distribution pattern of Thra and Thrb is age and
tissue dependent. While TRa1 is widely expressed, TRb
1–2 mRNA expression is restricted to specific ontogenetic
states and is highly tissue specific(128). Based on knock-
out and knock-in experiments, Thra was found to influ-
ence cardiac functions, thermogenesis, haemopoiesis, and
the maturation of intestines and bones(128–131). Thrb is
crucial for the proper endocrine and sensory functions
such as the hypothalamic–pituitary–thyroid axis, hepatic
reactions to T3, behaviour, audition, colour sensation and
tactile senses(132–138). TRa1 and TRb1 isoforms can be
co-expressed in the same tissues and can substitute for
each other’s function to a certain extent(138,139).
Nutrients entering the small intestines elicit enterogluca-
gon production in the intestinal wall that reaches the liver
before the absorption of the nutrients(140). Absorbed nutri-
ents quickly enter the liver through the portal vein. Carbo-
hydrates, and to a lesser extent proteins, induce hepatic D1
gene expression(141–143) and down-regulate D3 activity. T3,
in turn, increases hepatic and muscular GLUT (GLUT-1 and
GLUT-5) gene expression(101,144). The latter also enhances
hepatic thyroid hormone activation(145). Increased energy
intake, therefore, induces increased plasma T3 concen-
tration that increases BMR(117). Increased, but still physio-
logical plasma T3 concentrations, in turn, trigger appetite
in the hypothalamic ventromedial nucleus. This is a self-
strengthening mechanism(146,147).
In piglets, thyroid hormone plasma concentration
(mostly T3) increases sharply after food intake, reaching
its peak after 60 min. The rise in thyroid hormone concen-
tration mainly depends on the energy content of the food
and is relatively independent from the glucose concen-
tration of the blood(101). In contrast to feeding, starvation
elicits a decrease in plasma T3 concentration in mammals.
T4 response to starvation, however, depends on the
species. For example, starvation leaves plasma T4 concen-
tration unaffected in humans(148), but in rats(149,150) and
swine(151–153) plasma T3 concentrations drop after star-
vation. In chickens, starvation causes decreased plasma
T3 and increased plasma T4 concentration
(115,154–157) due
to increased hepatic D3(111) and decreased hepatic D2
activity and gene expression(158). In cows, effects of star-
vation are difficult to examine due to the characteristics
of rumen function. Therefore, the effect of fluctuations in
feeding on plasma thyroid hormone concentration was

















tested and it was found that reduced food intake resulted
in decreased plasma thyroid hormone concentration(159).
Dairy cows represent a unique category with regard
to thyroid hormone physiology. These animals can enter
a physiologically starvation-like period during lactation
when energy metabolism turns towards so-called negative
energy balance. Under such conditions, plasma T4 concen-
tration reaches its nadir and T3 plasma concentration
is low. Later, plasma thyroid hormone concentrations
increase and reach their peak during the dry period(159).
Romo et al.(160) and Pezzi et al.(117) found that hepatic
D1 activity is the lowest during early lactation and
suggested a possible role of fatty liver in the decreased
enzyme activity and the consequently decreased hepatic
thyroid hormone activation. However, decreased feed
(and consequently carbohydrate) intake can also be
acting in the background of decreased thyroid hormone
activation since T4-to-T3 conversion is a carbohydrate-
dependent process(141) and glucose directly triggers
hepatic D1 expression(143).
As mentioned above, hypothalamic NPY/AgRP neurons
are in a special position to trigger food intake, and both
leptin and ghrelin are able to influence the activity of
these cells. Coppola et al.(161) clearly demonstrated that
arcuate nucleus NPY/AgRP neurons are supplied with T3
by hypothalamic tanycytes, and that T3, imported from
tanycytes, can activate intracellular mechanisms in NPY/
AgRP cells to increase neuronal firing and, consequentially,
to initiate food intake. These observations imply a possible
interaction between the three hormones discussed so far,
in the regulation of NPY/AgRP neuronal activity. However,
according to Ishii et al.(162), subcutaneously injected T3
results in hyperphagia via hypothalamic adenosine mono-
phosphate activated protein kinase (AMPK) phosphoryl-
ation, without affecting local (hypothalamic) NPY or
POMC mRNA expression levels, suggesting that additional
mechanisms may also be involved in the hypothalamic
regulation of food intake.
Oestrogen
Traditionally, oestrogens (mostly 17b-oestradiol; E2) have
been regarded exclusively as sex hormones, and, indeed,
many of their direct actions are exerted on reproductive
organs and tissues. Oestrogens are primarily synthesised
within the developing follicles of the ovaries and exert
an influence on the female reproductive system. However,
other sites of biosynthesis are present throughout the body,
including the adipose tissue and the brain itself. Adipose
tissue contributes significantly to the maintenance of
plasma concentration of E2. Besides the adipose tissue,
aromatase (oestrogen synthase) expression is also found
in muscle, skin fibroblasts, osteoblasts and chondrocytes
of bones, vascular endothelial and aortic smooth muscle
cells, Leydig cells, as well as a number of sites in the
brain including the medial preoptic/anterior hypothalamus,
the mediobasal hypothalamus and the amygdala(163,164).
Oestrogens exert an effect on almost every cell type, regu-
lating an eclectic assortment of functions.
In males, regulation of E2 mainly occurs through
the conversion of testosterone using aromatase enzyme
throughout the body, including the adipose tissue that
represents a major source of ovary-independent pro-
duction(164). A positive relationship was described between
BMI and plasma E2 levels in men and postmenopausal
women, and circulating levels of E2 decreased in response
to fasting or energy restriction in fertile women(165). Rats
lacking oestrogen receptor a (ERa) or aromatase have
increased fat mass and hyperlipidaemia(166). This suggests
that E2 has a role in signalling the central nervous system
about the status of peripheral energy stores.
It has long been known that E2 modulates
hunger(166–168). The question, however, of how much is
the share of E2 alone, besides other relevant hormones,
in the regulation of food intake is not fully known. Apart
from the actual initiation of food intake, effects on
energy expenditure highly influence evolving hunger sig-
nals. Therefore, E2 can modulate feedback hunger signals
through its central and peripheral regulatory role in the
initiation of heat production(169). The homeostatic func-
tions of E2, such as reproduction, stress responses, feeding,
sleep cycles and temperature regulation were originally
thought to be mediated through E2’s classical intracellu-
lar/nuclear receptors (oestrogen receptors) ERa and
oestrogen receptor b (Erb), which act as transcription
factors, binding to the oestrogen-responsive elements
(ERE)(170,171) of respective genes. Keeping with the general
context of the present review, a recent study reported that
elimination of ERa (ERaKO) from the hypothalamic
ventromedial nucleus in rats leads to the development of
the metabolic syndrome, with a significant deficit in
energy expenditure(172). In addition to nuclear oestrogen
receptors, there are other extranuclear pathways activated
after ligands bind to the oestrogen receptor in the plasma
membrane(173,174), or activate intracellular proteins directly
responsible for the regulation of cellular energy levels,
such as UCP(175) or ectonucleotidases(176). Oestrogens can
also initiate cellular actions through membrane-bound
E2-sensitive molecular complexes, such as G-protein-
coupled receptor 30, ion channels and receptors for
other ligands(177). An interesting mechanism of oestrogenic
effects is the synaptogenic influence of E2 on hypothalamic
neuronal connectivity. It is now well established that E2
induces synaptic reorganisation in the hypothalamus to
regulate the secretion and release of gonadotropin-releas-
ing hormone and, consequentially, pituitary luteinising
hormone release(178). Synaptic plasticity plays a crucial
role in the hypothalamic mediation of leptin and ghrelin
effects as well(179), and overall synaptic reorganisation in
the hypothalamus seems to be shaped by all three hor-
mones (E2, leptin and ghrelin). However, E2 appears to
exert its own synaptogenic influence in the hypothalamus,

















since apart from the ovarian cycle, hunger is also modu-
lated by the actual levels of E2(167,168). It is now well estab-
lished that oestrogens (E2 above all) are trophic hormones.
As such, a plethora of studies reported that E2 interacts
with other trophic hormones, including the ones discussed
in the present review, to regulate developmental events
and energy metabolism (food intake and energy expendi-
ture)(180–183). A relevant selection of these interactions
will be discussed below. At this point, we only note that
E2, while targeting hypothalamic neurons, is able to influ-
ence the function of NPY/AgRP-containing neurons of the
arcuate nucleus, the major mediators–initiators of food
intake, and thus play a significant role in shaping the over-
all outcome of NPY/AgRP neuronal activity(179,182). The
latter role includes a blunting effect after fasting-induced
activation of these neurons(183). Interestingly, however,
E2 not only attenuates hunger by down-regulating relevant
hypothalamic ‘hunger cell’ activity (NPY/AgRP neurons),
but also modulates neurotransmission on POMC neurons
(satiety cells) to attenuate the cannabinoid-induced
changes in appetite(184).
Insulin
Insulin is secreted by pancreatic islet cells (b-cells) and is
known as a major regulator of blood glucose levels. To
date, a large body of evidence demonstrates actions of
insulin in the hypothalamic feedback loop of energy bal-
ance regulation(185). The actual concentration of plasma
insulin is proportional to body adiposity, although it also
depends on food consumption and type of diet. Secretion
and synthesis of insulin are affected by a number of genetic
and environmental/epigenetic factors. Food intake, diet,
fasting and re-feeding influence insulin entry to the brain
or its ability to get into the brain tissue(186). Eating increases
the concentration of insulin in the brain whereas fasting
decreases the concentration. Plasma insulin levels directly
correlate with those measured in the cerebrospinal fluid.
Insulin enters the brain, crossing the blood–brain barrier
by a receptor-mediated transport, and stimulates anorexi-
genic pathways as an adiposity signal leading to reduced
food intake. Insulin receptors are expressed in hypothala-
mic neurons, predominantly in the arcuate nucleus(187), a
nucleus associated with the regulation of food intake,
energy expenditure and food reward and the site of several
orexigenic and anorexigenic neural signals(180,182,188,189).
In rats, hyperphagia caused by insulin-deficient type 1
diabetes can be reversed by intracerebroventricular
administration of insulin. Thus, insulin interacts with both
orexigenic and anorexigenic neuromodulators(189,190).
Reports from the past three decades show that insulin
exerts multiple effects in the brain, and its role has been
validated by the identification of receptors and transport
machinery in the central nervous system. Insulin acts on
hypothalamic circuits that regulate food intake, metabolism
and other crucial functions, and insulin-responsive neurons
include the hypothalamic NPY/AgRP neurons(191), the
latter which may represent a special cell population allow-
ing for a cross-talk between the major hormonal signals
discussed in the present review. The effects of insulin lead-
ing to decreased food intake are, at least in part, due to the
inhibition of NPY expression of neurons of the arcuate
nucleus(192). An interesting hypothalamic effect of insulin
was observed by Lin et al.(193), who found that hypothala-
mic NPY/AgRP and POMC neurons mediate insulin’s cen-
tral effects to regulate hepatic glucose production.
Part of the endocrine cross-talk appears to manifest in
the hormonal regulation of hypothalamic synaptic reorgan-
isation, where the interaction of insulin-like growth factors
and their receptors are a well-known episode in the regu-
lation of synaptic plasticity(178).
Despite the abundance of relevant data, a clearcut bor-
derline between the effects of insulin alone and those
exerted through the interactions of insulin with other per-
ipheral trophic hormones in the hypothalamic regulation
of food intake is not yet known. Therefore, further effects
of insulin on food intake will be discussed below in the
context of hormone interactions.
Hormone interactions and combined hormone effects
Interactions of ghrelin and leptin
In mammals, ghrelin stimulates food intake and appears to
act as the functional antagonist of leptin(194). There is a fine
balance between the two physiologically antagonistic
hormones as demonstrated by Giovambattista et al.(195),
who detected enhanced leptin secretion after prolonged
ghrelin exposure. In turn, moderate hyperleptinaemia/
leptin administration prevents the increase of plasma
ghrelin during short-term energy restriction(196). Ghrelin’s
hunger signal stimulates the hypothalamic regions
responsible for food intake in the lateral hypothalamic
nuclei and arcuate nucleus. In contrast to leptin, plasma
levels of ghrelin fluctuate in relation to food intake. The
low ghrelin levels in obese individuals are associated
with low growth hormone concentration and high
leptin levels(32,197). Rigamonti et al.(198) found higher con-
centrations of plasma ghrelin in young patients compared
with elderly patients. Thus, it is possible that a high
concentration of leptin suppresses ghrelin’s plasma
level. This idea is supported by observations that plasma
leptin concentration correlates with the body fat mass
which is high in obesity, decreased in fasting and low in
anorexia nervosa.
An interesting addition for ghrelin and leptin regulation
is the linkage to sleep–wake behaviour(17). It has been
demonstrated that inadequate or bad-quality sleep is
associated with changed levels of ghrelin and leptin, and
is in connection with energy balance disorders leading to
weight gain. Normally, ghrelin levels rise at night. In
sleep deprivation or insomnia, however, night-time ghrelin

















levels fall significantly and are followed by increased day-
time ghrelin levels. Administration of ghrelin increases the
ratio of non-rapid eye movement (REM) sleep in human
subjects. The REM phase is thought to be the stage with
the highest metabolic rate. Lack of it leads to hormonal
changes that increase appetite. It is noteworthy that insuf-
ficient sleep can decrease daytime levels of leptin; how-
ever, its nocturnal levels do not show significant change
between healthy individuals and insomniacs.
The anatomy and synaptology of the hypothalamic
leptin/ghrelin-responsive neurons provide an explanation
for the aforementioned interactions. In a review, Hor-
vath(179) pointed to the ability of hypothalamic neuronal
circuits to rearrange themselves in response to peripheral
and central hormone effects. Earlier, this phenomenon
had not been considered as part of the mechanism respon-
sible for the regulation of daily energy metabolism. How-
ever, as stressed in that review, experiments on ob/ob
mice and transgenic animals provided clearcut evidence
for the ability of leptin and ghrelin to induce synaptic
reorganisation on hypothalamic neurons that are in a key
position (NPY/AgRP and POMC cells) to regulate food
intake and other determinants of energy homeostasis.
Hypocretin/orexin-containing neurons of the lateral
hypothalamus are major targets of gastric ghrelin and, at
the same time, these neurons directly innervate raphe
serotonergic neurons to regulate sleep–wake behaviour.
Elevation of serum ghrelin levels increases the number of
excitatory synapses and the ratio of stimulatory/inhibitory
synapses on lateral hypothalamic hypocretin/orexin neur-
ons. Since such a ratio in cellular synaptic status is a key
factor in the shaping of neuronal activity, the consequence
of such a synaptic reorganisation is that the neurons in
question, as major sources of the stimulatory innervation
of arcuate nucleus NPY/AgRP cells, increase the activity
of the latter cell population, thereby initiating/increasing
food intake. Such synaptic plasticity occurs simultaneously
on POMC neurons as well, where an inhibitory dominance
occurs at the time of increased NPY/AgRP cell activity. The
described synaptological basis of the mechanism includes
the anti-ghrelin-like (antagonistic) effects of leptin, but is
also modulated by the synaptogenic effects of E2 and
other hormones discussed in the present review.
Interactions of ghrelin and insulin
As mentioned above, ghrelin release is not influenced by
simple expansion (mechanical distention) of the stomach;
instead, it is highly dependent on the ingredients of the
meal. Elevated blood glucose level, after oral or intra-
venous application, leads to decreased plasma ghre-
lin(197,199,200). In turn, ghrelin seems to enhance the
degradation/catabolism of carbohydrates and results in
an increase in the RQ. According to Ariyasu et al.(36),
insulin-induced hypoglycaemia facilitates ghrelin secretion
in rodents and this can be reversed by glucose injections.
Ghrelin levels are increased under lipid-rich diets, but
not under low-protein diets(201,202).
As emphasised in the present review, the arcuate
nucleus is a key brain region regulating energy balance.
Peripheral hormonal signals converge to influence arcuate
nucleus circuits and shape overall energy metabolism.
Among these signals are ghrelin and insulin, whose
common targets are the arcuate nucleus NPY/AgRP neur-
ons, the ‘hunger cells’ of the hypothalamus. As described
above, ghrelin stimulates the activity, while insulin
down-regulates NPY secretion of these cells; thus these
two hormones antagonise in the regulation of ‘hunger
cell’ function. Apart from their hypothalamic effects, paral-
lel brain circuits are also modulated by the two hormones.
For example, there is evidence that brainstem regions, such
as the ventral tegmental area, are sensitive to leptin, insulin
and ghrelin and that the activity of dopaminergic cells of
the ventral tegmental area are modulated by the above hor-
mones(203,204). In turn, the ventral tegmental area dopamin-
ergic cells innervate a number of forebrain structures,
forming circuits that are commonly associated with the
expectation of feeding-associated reward(205–207).
It is noteworthy that besides their central effects, there
are certain peripheral interactions of ghrelin and insulin
that also influence hypothalamic neural mechanisms. For
example, a wide range of findings supports roles of ghrelin
in the regulation of insulin release. Ghrelin receptors are
present on insulin-secreting b-cells(21) and ghrelin immuno-
reactivity is reported in pancreatic islets partly overlapped
with glucagon-immunoreactive cells. Data suggest that
ghrelin is synthesised and secreted in pancreatic a-cells
and feeds back on the same a-cells in an autocrine and/
or paracrine manner. Ghrelin concentration in pancreatic
veins is higher than in pancreatic arteries, suggesting that
pancreatic islets produce ghrelin as well(208,209). In support
of the latter, in their review, Dezaki et al.(210) described that
ghrelin is present in pancreatic islet cells and regulates
b-cell insulin secretion.
It was recently established that (exogenous) ghrelin
administration increases plasma glucose and reduces insu-
lin levels(211). These results are supported by the finding
that ghrelin knock-out mice show elevated insulin pro-
duction in pancreatic islets, which leads to decreased
blood glucose levels(212,213). The main regulator of insulin
release seems to be the glucose-induced Ca influx into
the b-cells. Dezaki(213) described the Ca-mediated insulin
release that could be attenuated by ghrelin administration.
The mechanism underlying this observation involves ghre-
lin’s activating effect on b-cell growth hormone secretago-
gue receptors (GHS-R) to enhance Kþ currents through
delayed rectifier K-channels via G-protein activation; this,
in turn, attenuates the glucose-induced Ca influx and
thereby decreases insulin secretion(210).
Yet another finding to consider is that ghrelin attenuates
the expression of UCP2 in ob/ob mice, which, under
normal circumstances, down-regulates glucose-induced

















ATP production, reducing insulin release from b-cells. In
summary, ghrelin inhibits insulin secretion in islet b-cells
in two ways: (1) by acutely enhancing Kv channels and
suppressing Ca signalling; and (2) by chronically up-regu-
lating UCP2. Consequently, ghrelin inhibits insulin release,
thereby increasing glycaemia, and affecting feeding beha-
viour and adiposity(210,211).
Interactions of leptin and thyroid hormones
Both leptin and the thyroid hormones are key regulators of
body weight by affecting food intake and energy expendi-
ture(214). Leptin decreases food intake and increases energy
expenditure, while the thyroid hormones T4 and T3
increase both food intake and energy expenditure. This
indicates that thyroid hormones and leptin could play a
crucial role in the regulation of the balance between
energy intake and energy expenditure, and, consequently,
in the regulation of body weight and body fat mass. The
correlation between serum leptin and T3 concentrations
has been studied extensively. Results so far are conflicting,
particularly those from human studies(215).
Study on cultured rat adipocytes demonstrated that
leptin mRNA production and thus leptin secretion was
inhibited by Triac (triiodothyroacetic acid, a metabolite of
T3) and T3 in a dose-dependent manner and with similar
potency(216). This was confirmed in an in vivo rat study,
in which intraperitoneal administration of different doses
of T3 (and consequently increased serum T3) led to a
decrease in white adipose leptin mRNA levels and a
decrease in serum leptin concentration. This observation
indicates that T3 regulates serum leptin through the modu-
lation of leptin gene (ob) expression(205).
Conversely, administration of leptin has been shown to
affect serum thyroid hormone levels. When administered
to fasted rats, leptin prevented the reduction in thyroid
hormone levels by maintaining normal pro-thyrotropin-
releasing hormone (precursor to thyrotropin-releasing hor-
mone) mRNA activity in the hypothalamus(217). Likewise,
leptin enhanced T4-to-T3 conversion
(217). Leptin also pre-
vents the suppression of TSH in the anterior pituitary
after food restriction, thereby maintaining serum T3 and
T4 levels. However, this anti-inhibitory effect of TSH also
depends on thyroid gland activity, as it was not observed
in hypothyroid rats(218).
In the brain, T4-to-T3 conversion is catalysed by D2.
According to Coppola et al.(161), in the arcuate nucleus,
D2 activity takes place in tanycytes, and resulting T3 is
then transferred to NPY/AgRP neurons. T3 in the latter
cell population triggers a series of events including the
up-regulation of UCP2 and NPY, eventually leading to
mitochondrial proliferation and increased neuronal
activity. The physiological outcome of these cellular
events manifests in the initiation of or in an increase in
food intake. As previously mentioned, leptin up-regulates
uncoupling in UCP2-expressing hypothalamic neurons.
This might be, at least in part, due to leptin’s ability to
increase T3 levels by acting centrally on D2 activity
(219).
Interestingly, however, as an anorexigenic hormone,
leptin down-regulates NPY/AgRP neuronal functions.
Therefore, in terms of food intake, it seems likely that
T3’s and leptin’s opposing physiological effects on NPY
neurons are mediated by different signalling modalities
with possible cross-talk at the level of UCP2. UCP2, and
other uncoupling enzymes elsewhere in the body, may
be common targets of T3 and leptin in their regulatory
actions in heat production. The latter regulatory process
probably involves parallel neural circuits. For example,
the expression level of UCP1 in brown adipose tissue is a
marker of sympathetic nervous system activity. It has
been shown that D2 activity, in brown adipose tissue in
particular, can be stimulated by the sympathetic nervous
system(219) and, not surprisingly, central leptin adminis-
tration increases UCP1 expression in brown adipose tissue.
In sum, T3 regulates serum leptin levels by inhibiting
leptin gene expression, but leptin maintains normal thyroid
hormone levels in food-restricted animals by preventing
the suppression of thyrotropin-releasing hormone and
TSH(220). Leptin also increases D1 activity peripherally,
and D2 activity centrally in food-restricted animals, result-
ing in an increase in T3 as long as sufficient T4 is available.
Interactions of oestrogen and leptin
The interactions of E2 and leptin are particularly interesting
and deserve more attention, since the two hormones have
similar effects on food intake and energy homeostasis. For
example, leptin limits food intake, i.e. decreased leptin
levels result in hyperphagia. Oestrogen also mimics this
effect: ovariectomy leads to increased food intake that
can be reversed by E2 replacement.
Noteworthy among their interactions are the two hor-
mone’s effects on the regulation of each other’s plasma
levels. Such effects are exerted through indirect and
direct pathways. Leptin influences E2 levels indirectly by
modulating the regulation of the reproductive axis. It is
well known that undernutrition inhibits female reproduc-
tive functions and lowers ovarian E2 in favour of self-main-
tenance and thermoregulation(221–223). Low levels of
ovarian E2 during fasting can be increased by eliminating
leptin deficiency. Similarly, low E2 levels in ob/ob mice
can also be increased by leptin(165). Furthermore, leptin
administration increases basal luteinising hormone levels,
ovarian uterine weights and restores fertility in ob/ob
mice(221). This suggests that leptin could be the adiposity
signal to the reproductive axis signalling the body’s current
nutritional status, allowing reproduction to continue if
significant adipose tissue is available and inhibiting it
if body fat stores are depleted(224). The inhibiting effect
of leptin deficiency on reproduction is mediated
through the down-regulation of gonadotropin-releasing
hormone(165,225).

















Although gonadotropin-releasing hormone secretion
appears as an important platform of leptin influence on
oestrogenic effects, leptin may also influence cellular E2
availability directly. Leptin stimulates aromatase activity
in adipose tissue and the presence of leptin receptors
(Ob-R) in the ovary implies that leptin may have direct
influence on ovarian E2 production and/or oestrogenic
effects(165).
There is evidence suggesting that leptin production is
directly affected by E2. Ovariectomy or deletion of ERa
increases serum leptin levels and leads to an increase of
body fat mass(166). Plasma leptin levels are higher in
women than in men with an equivalent fat mass and
leptin secretion is higher in isolated female omental
tissue than male donors, suggesting that sex steroids
exert effects on leptin production. Women have higher
subcutaneous tissue fat and less intra-abdominal fat than
men. Therefore, this sex-related difference in fat distri-
bution may account for these sex differences in leptin
levels. Conversely, administration of E2 to cultured rat adi-
pocytes induces leptin secretion and E2 receptors have
been found in adipose tissue, suggesting that E2 exerts
its effects over leptin secretion directly on adipocytes(165).
In ovariectomised rats, the minimum effective leptin
dose resulting in weight loss is greater than in controls,
implying that E2 deficiency may attenuate leptin’s
effects(165). A number of further studies confirm this attenu-
ating effect of E2 over leptin and provide more insight into
the potential mechanism. Meli et al.(166) found that changes
in body weight and fat content caused by ovariectomy are
accompanied by alterations in serum leptin concentration.
Serum leptin levels are higher in ovariectomised than sham
controls, and are reversed by E2 treatment. Increased
serum leptin levels after E2 withdrawal are secondary to
the increase in fat mass. Mid- or long-term hypo-oestrogen-
ism causes a lower expression of Ob-R in adipose tissue
and the hypothalamus compared with sham-operated
rats. Lack of E2 leads to hypothalamic NPY overproduction
and impairs central leptin sensitivity. The decrease in Ob-R
and the associated leptinaemia support central leptin
insensitivity. Oestrogen status, therefore, modulates
serum leptin levels, as well as hypothalamic and white adi-
pose Ob-Rb expression, thereby implying close cross-talk
between central and peripheral leptin sensors in the regu-
lation of body fat mass.
The above phenomenon was observed outside of the
hypothalamus as well: Chen et al.(226) found a relationship
between E2 levels and Ob-R expression in the dorsal root
ganglion. Oestrogen was found to increase the expression
of Ob-R protein and mRNA in ovariectomised rats. As a
result of co-labelling for Ob-R and ERa/ERb, 100 % co-
localisation of ERa with Ob-R occurred, while ERb–Ob-R
co-localisation occurred in only 15 % of dorsal root
ganglion neurons. The authors concluded that E2 may
up-regulate the expression of Ob-R protein and mRNA in
an ERa-dependent manner.
A study by Ainslie et al.(227) confirmed that E2-deficient
rats may be leptin insensitive. The authors showed that
the effect of central leptin administration on food intake
and physical activity in ovariectomised rats is significantly
less than in sham controls. However, they did not find
differences in Ob-Rb mRNA expression between sham
and ovariectomised rats, suggesting that central leptin
insensitivity may occur due to a defect at, or downstream
to, the hypothalamic Ob-Rb itself.
Once leptin binds to Ob-Rb, the associated Janus kinase
2 tyrosine kinase is activated, followed by the activation of
signal transducer and activator of transcription 3 protein
(STAT3), STAT5, phospatidylinositol 30-kinase and MAPK
pathways. STAT3 is a crucial member of these pathways,
as ablation of Ob-Rb–STAT3 signalling/neuronal STAT3/
STAT3 in Ob-Rb neurons mimics the obesity, hyperphagia
and decreased energy expenditure of leptin-deficient
db/db mice. Following phosphorylation of STAT3 by
Janus kinase 2 and the subsequent dimerisation and
nuclear transport, STAT3 alters cell transcription and func-
tion. It was proposed that E2 may interact with the leptin
pathway at the level of STAT3. STAT3 has been reported
as a target of E2 signalling in cells. In a neural STAT3
knock-out murine model, mice exhibited obesity and infer-
tility which E2 administration failed to correct(182).
Oestrogen receptors are functionally linked to
STAT3: they have a direct physical coupling and involve
co-regulators such as cAMP-response element binding
protein. STAT3 also enhances the transactivational function
of oestrogen receptors, which suggests that oestrogen
receptors and STAT3 act mutually as co-activators to
facilitate signalling(182).
Conversely, Chen & Heiman(228) sought to determine
whether ovariectomy leads to leptin resistance. Ovari-
ectomy caused hyperphagia and increased fat mass.
Leptin treatment increased fat utilisation and prevented
reduction in energy expenditure. Withdrawal of leptin
stimulated hyperphagia. The authors concluded that loss
of ovarian function in rats is not associated with a
change in leptin sensitivity.
It is well established that the hypothalamus plays an
important role in the regulation of food intake and body
weight since chemical or physical lesions of these regions
cause hyperphagia and obesity(165,182). It seems clear at this
point that the combined effects of leptin and E2 are exerted
by their actions on the same population of hypothalamic
neurons(229). Evidence indicating that E2 and leptin may
cooperate in the regulation of energy metabolism and
reproduction is provided by the co-localisation of E2 and
leptin receptors in hypothalamic neurons. Diano et al.(230)
reported co-localisation of leptin receptors with ERa in the
medial preoptic area, arcuate nucleus, ventromedial
nucleus and paraventricular nuclei in female rats. The
authors suggested that this extensive co-localisation of
receptors in neuronal perikarya of the hypothalamus indi-
cates a functional link between these hormones and the

















regulation of a variety of behavioural and neuroendocrine
mechanisms. In a previous study, Meli et al.(166) also found
considerable co-localisation of oestrogen receptors and
Ob-R in hypothalamic nuclei.
The possible mechanisms through which E2 and leptin
may cooperate in the brain include interrelated modifi-
cations of hypothalamic orexigenic and anorexigenic
neuropeptides. In the hypothalamus, anorexigenic arcuate
nucleus POMC neurons inhibit food intake through the
release of the cleavage product melanocyte-stimulating
hormone, while the orexigenic NPY neurons act
against this to promote feeding(165). When leptin signalling
is diminished, or during fasting, POMC expression is
reduced, while increasing levels of leptin stimulate POMC
transcription through STAT3 activation(165,182). Mystkowski
& Schwartz(165) found that ovariectomy in rats leads to
increased POMC expression in the arcuate nucleus, imply-
ing an adaptive response of POMC neurons to attenuate
increases in body weight. Furthermore, decreased body
weight following the administration of supraphysiological
amounts of E2 in male rats is followed by the induction
of arcuate nucleus POMC gene expression. Oestrogen-
induced weight loss elicits a compensatory reduction of
POMC gene expression. Therefore, increased melanocortin
signalling does not mediate E2 effects on energy
homeostasis.
Gao & Horvath(182) claim, however, that E2 exhibits mol-
ecular and cellular effects on POMC similar to leptin in the
arcuate nucleus. They state that both leptin and E2 alter the
synaptic input on hypothalamic melanocortin neurons,
inducing an increased POMC tone and decreased food
intake and adiposity, allowing for the assumption that E2
and leptin regulate POMC expression by the induction of
synaptic remodelling.
According to Hirosawa et al.(231), the increased serum
leptin levels did not up-regulate POMC expression in the
hypothalamus of ERa-null mice, while ablation of E2 by
ovariectomy and the accompanying higher serum leptin
levels up-regulated POMC expression, indicating that ERa
is essential for the up-regulation of POMC and that this
pathway is probably mediated in an E2-independent
manner. ERa can be transcriptionally activated by ligand-
independent activation. The authors suggest that leptin
may activate ERa through the MAPK pathway via Janus
kinase 2. Others, however, suggest that E2 influences
the distribution of body fat and adipose tissue
metabolism via both ERb and ERa: according to Shin
et al.(232), obesity and blood leptin levels are influenced
by the ERb:ERa ratio.
It may be possible that E2 exerts its effects over POMC
via a putative membrane-associated oestrogen receptor
that is distinct from ERa and ERb. Qiu et al.(171) identified
this receptor in dopamine-containing and POMC hypo-
thalamic neurons; its activation leads to desensitisation of
g-aminobutyric acid (GABAB) receptors in POMC neurons
of the arcuate nucleus by the phospholipase C, protein
kinase C, protein kinase A pathway, facilitating the for-
mation of synaptic contacts with hypothalamic areas
controlling appetite by POMC neurons.
Interactions between insulin and leptin, oestrogen or
thyroid hormones
Leptin, like insulin, plays an important and key role in
food reward. The mechanisms are unclear but are
being intensely investigated(233). Insulin is a major
modulator of leptin levels(234–239), in a dose-dependent
manner(240–242). In diabetic rats, insulin administration
reverses the previously reduced leptin level(243). Hypo-
thalamic neurons (predominantly in the arcuate nucleus)
that express leptin receptors(82) and insulin recep-
tors(244–246) widely overlap. In these neurons, the signal-
ling pathways of leptin and insulin converge on PI3
kinase whose product, PIP3, regulates excitability of ATP-
dependent K (KATP) channels, thereby controlling food
intake, energy expenditure and glucose metabolism(247).
The activation of KATP channels results in hyperpolarisation
and thereby inactivation of glucose-responsive/insulin-
sensitive neurons. It has been shown that the inhibition
of PI3 kinase blocks the anorexigenic effects of both
leptin and insulin in rats(188). Insulin and leptin both
target arcuate nucleus NPY neurons, where PI3 kinase-
mediated signals seem to be shared and are common reg-
ulators in the two hormones’ activating effects(248). Insulin,
in interaction with serotonin and leptin, affects the activity
of POMC neurons, inducing a-MSH release, which leads to
a negative regulation of energy balance.
It has been reported that both ERa knock-out and
aromatase knock-out mice are obese(249,250), but ovari-
ectomised ERa knock-out mice display decreases in body
weight, fat-pad weight, adipocyte size and improved insu-
lin and glucose metabolism indicative of ERb-mediated
activity on adipose tissue which are opposite to those of
ERa(251). ERa plays a role in the development of hepatic
insulin sensitivity(252,253) since the absence of ERa in the
ventromedial nucleus leads to weight gain and insulin
resistance, adiposity, hyperphagia and hyperglycaemia(172).
It is well known that the insulin-activated GLUT-4 transpor-
ter is the main carrier for glucose into cells. In ERa knock-
out mice, the activity of these transporters is substantially
reduced; ERb knock-out mice do not show this
deficiency(254). Insulin–E2 interactions are also obvious
in certain physiological or pathological conditions, such
as pregnancy, menopause or diabetes. In pregnant rats,
sexual steroid levels are increased, resulting in elevated
insulin levels. Likewise, E2 administration in menopausal
women corrects insulin secretion and decreases insulin
resistance(255–257). Cellular investigations demonstrate that
ERa is also present in pancreatic b-cells, which is respon-
sible for the short-term insulinotropic effect of E2 via inhi-
bition of KATP channels.

















A hypothesis has arisen that partially explains the
synergistic interrelationship of insulin and T3 underlying
mechanisms involved in glucose and lipid metabolism.
According to this, T3 plays a more significant role in glu-
cose metabolism and regulation than previously thought.
T3 regulates glucose uptake, storage, glycolysis, as well
as lipid oxidation and uptake in insulin-sensitive cells.
Disturbances in T3 levels cause insulin resistance and
hyperglycaemia, which is indicative of its contribution to
deficiencies/pathogenesis leading to type 2 diabetes. T3
increases glucose uptake directly. Expression of (regulat-
ory) glucose transport proteins, such as GLUT-1, GLUT-2
and GLUT-4 are regulated by both insulin and T3. A
family of membrane-associated proteins regulated by T3,
named b3-adrenergic receptors, plays a role in NEFA
oxidation and insulin secretion. T3 and TAG in fat cells
regulate insulin secretion and insulin sensitivity by an as
yet unknown mechanism(258–266). Additionally, T3 regu-
lates the expression of transmembrane enzymes Kþ/Naþ
and Ca2þ ATP-ase, involved in driving membrane-bound
protein pumps, which transport molecules such as glucose
and amino acids into the cells(267). Thyroid hormones
reduce b-cell mass, the main source of insulin production,
although several studies have demonstrated that thyroid
hormones have cytotoxic effects on b-cells in vivo and
in vitro. In fact, thyroid hormones induce apoptotic cell
death in insulin-producing cells(268–272).
Interactions between oestrogen and thyroid hormones
Although clinical reports point to a relationship between
thyroid disorders and insulin sensitivity particularly preva-
lent in older populations of females more than males, the
mechanisms which link sex steroids, thyroid hormones
and metabolic homeostasis in both sexes are not well
known(273). In postmenopausal women receiving E2 treat-
ment, lower levels of free T3 and free T4 have been
observed although there was no rise in serum TSH(274).
Although E2 treatment did not alter the serum concen-
trations of TSH in euthyroid or untreated hypothyroid
rats, it increased the T3 effect in serum TSH in hypothyroid
rats. Oestrogen treatment increased thyroid hormone
receptor expression in the pituitary, suggesting that an
increase in thyroid receptors may be induced by E2 in
rats(275). During development, treatment with testosterone
and E2 had similar effects in both sexes, producing lower
levels of a and b subunit mRNA in exogenous sex ster-
oid-treated hypothyroid rats compared with hypothyroids
not receiving exogenous sex-steroid treatment. These
data suggest that gonadal steroids render the pituitary
thyrotroph cells more sensitive to thyroid hormones(276).
This mechanism between oestrogen receptor and thyroid
hormone receptor interaction will be explored further,
keeping in mind the relationship as it pertains to feeding,
appetite, metabolism and energy balance modulated by
sex hormones, particularly E2 in women.
Thyroid hormones affect reproductive behaviours of
both males and females in addition to playing a permissive
role in the photoperiodicity of both sexes(277–279). Both
thyroid hormones and sex steroids modulate metabolic
homeostasis and oxidative metabolism at the tissue level
via their respective non-genomic membrane and
genomic nuclear receptors, sometimes acting synergistically
between genomic and non-genomic mechanisms(280–286)
as described above. These mechanisms, in turn, feed
back into the regulation of the hypothalamo–pituitary–
adrenal axis, hypothalamo–pituitary–gonad axis, as well
as the ‘hypothalamus–gut’ circuits(287–289). Additionally,
thyroid hormones contribute to the maintenance of non-
reproductive conditions, homeostasis in both male and
female birds and mammals, for example, intracellular
sites of activity including mitochondria, endoplasmic reti-
culum, plasma membrane, synapse(124,290), lipogenesis,
lipolysis, thermogenesis, growth, development, differen-
tiation(124,291,292), mylenation of axons(293) via nuclear
recruitment of co-activators and co-repressors by ligand-
bound nuclear receptors(294). Mood and cognition in
women are also affected by E2 and thyroid hormones –
signals that underlie appetitive behaviour at converging
pathways in the hypothalamic nuclei, brain stem
and target organs of humoral and efferent
signals(283–285,287,295–297). Such mechanisms conduct
cross-talk among isoforms of nuclear oestrogen receptors
and thyroid hormone receptors in diverse tissues and in
terms of genomic expression(280,290,298–300). While it is
tempting to envision an overlapping function between oes-
trogen receptor and thyroid hormone receptor subtypes
and isoforms, different co-localisation studies indicate dis-
tinct non-overlapping functions(290). In support of this
idea, the phenotypes of the specific knock-out models
suggest functions unique to specific isoforms(294). On the
other hand, the modulation of the signals arising from E2
and thyroid hormones converging must influence under-
lying behaviour, such as appetite, feeding, homeostasis
and metabolism, concentrated in hypothalamic nuclei.
Two genes, Thra and Thrb, encode the mammalian
nuclear receptors for T3, confirming that T3 acts directly
on transcription. TRa1 (and TRa2)(291,300) is encoded by
the Thra gene, and TRb1 and TRb2 are encoded by the
Thrb gene; another TRb3 isoform that may be rat
specific(301). These receptors have a similar, if not identi-
cal, structure, containing a central DNA-binding domain
and a C-terminus domain, which activates transcription
upon ligand binding(302). Both oestrogen receptors and
thyroid hormone receptors are ligand-dependent nuclear
transcription factors that can bind to an identical half-
site, AGGTCA, of their cognate hormone response
elements, although generalisations of receptor cross-
activity are not easily made. For example, co-transfection
of a mutated TRa1 also inhibited the E2 effect without
binding to the AGGTCA sequence(303). Studies of inhibi-
tory effects of liganded TRa1 on E2 induction suggest

















that oestrogen receptors and thyroid hormone receptors
may interact to modulate E2-sensitive gene expression,
in a ligand-dependent and isoform-specific manner such
as for the hypothalamic preproenkephalin promoter(303).
However, in contrast to TRa, the isoforms TRb1 and
TRb2 failed to inhibit E2-induced activation of the consen-
sus ERE but, rather, attenuated E2-mediated transcriptional
activation(297). Thus, oestrogen receptor and thyroid
hormone receptor isoforms have modular protein struc-
tures with high homology in the central DNA-binding
domain where they bind common enhancer elements
(ERE) within the promoter sequence modulating gene
transcription(280,297,304–309).
Thyroid hormone receptors and oestrogen receptors are
members of the nuclear receptor superfamily, composed of
forty-eight ligand-activated Zn-finger transcription factors
involved in important physiological functions such as
metabolism and energy homeostasis, carbohydrate and
lipid metabolism in addition to development, reproduc-
tion, etc(304,305,310,311). Briefly, members of the superfamily
of nuclear receptors reside in either the cytoplasm or
nucleus of the cell. When ligands or small molecules
bind to the cytoplasmic nuclear receptor complex, it
undergoes conformational change, dimerisation and trans-
location to the nucleus where it binds to a sequence of
DNA called the hormone response element. There the
nuclear receptor complex then co-recruits or co-represses
other proteins downstream at the promoter site where tran-
scription factors are activated and changes in cell function
ensue.
Specifically, half of the T3 consensus response element
DNA sequence is identical to the oestrogen receptor
response element (ERE); therefore thyroid hormone
receptors bind to a consensus ERE(297,300,306,307,312) on sev-
eral receptor genes in the hypothalamus. Thyroid hor-
mone receptors and oestrogen receptors are both
present in rat hypothalamic nuclear extracts and bind to
the promoter regions in the hypothalamic gene preproen-
kephalin, causing interations between liganded thyroid
hormone receptors and oestrogen receptors that affect
preproenkephalin transcription(296,312). Likewise, the oxy-
tocin gene promoter has a composite hormone response
element to which several members of this superfamily of
nuclear receptors can bind to whereby thyroid hormones
interfere with E2-stimulated oxytocin mRNA reducing E2-
stimulated behaviour(300,307). The ERE identified in the
promoter region of the progesterone receptor is also
bound by thyroid hormone receptors(297). Progesterone,
important in reproductive behaviour, correlates with a
rise in appetite in cycling women(313). Thus, since T3
may reduce E2-dependent sexual behaviour through inter-
actions between thyroid hormone receptors and oestro-
gen receptors in the nuclei of hypothalamic neurons
which underlie sexual behaviour(303), their interaction
may modulate eating behaviour in women throughout
the cycle by acting at the nuclear receptor superfamily
concensus ERE as outlined above. Indeed, cursory
searches for feeding and oestrogen receptors, thyroid
hormone receptors, progesterone receptor, oxytocin and
preproenkephalin return hundreds of papers altogether
on feeding and each of the factors referred to above.
Over the past 30 years much has been explored on
the interaction of thyroid hormones and E2 at regions
of DNA co-activating and co-repressing genomic
expression(314) and the non-genomic membrane-initiated
molecular mechanisms of hormone signalling(309), i.e. the
cross-talk that produces a synergy between activation and
repression of genomic and non-genomic mechanisms(310).
Using a reproductive behavioural assay of rats, i.e. lordosis,
it has been shown that sex hormone-dependent hypothala-
mic gene expression and behaviour are influenced by
synaptic inputs which interfere with oestrogen receptor-
dependent neuroendocrine function and behaviour(314).
For example, the two different genes that code for TRa1
and TRb have opposite effects on female sexual beha-
viours(290,308), whereas hypothalamic neurons that express
E2-sensitive genes, for example, the preproenkephalin
promoter, are inhibited by TRa1 in the ventromedial hypo-
thalamus (VMH) but not the amygdala or caudate/
putamen(303,307,310). High doses of thyroid hormones
reduce lordosis behaviour of ovariectomised E2-treated
female mice(315) but in total pituitary RNA levels, depen-
dent upon new protein synthesis, E2 induced increases
while T3 inhibited E2 induction
(316). Studies of sex speci-
ficity between E2 and thyroid hormones in the regulation
of pituitary function found that pituitary weight and
total cellular RNA levels were significantly decreased fol-
lowing ovariectomy in females but increased following
gonadectomy in males without changes in pituitary DNA
levels compared with intact rats. Oestrogen treatment pro-
duced a significant increase in pituitary RNA in ovari-
ectomised females but not gonadectomised males,
although concomitant administration of T3 blocked the
increase in pituitary RNA in females(314). In contrast,
thyroid hormone inhibited ERa proteolysis in pituitary
lactotropes, did not prevent induction of prolactin gene
expression or proliferation and inhibited the ERE reporter
gene, suggesting that other endocrine factors can indirectly
modulate ERa activity(316).
Thyroid hormone receptor is known to bind an ERE
which inhibits E2-dependent transactivation(317). Areas of
the brain involved in reproductive functions and behaviour
may play a role in other appetitive behaviours such as
appetite and food seeking, namely the olfactory bulb, hip-
pocampus and granular layer of the cerebellar cortex,
where TRa1 and TRa2 transcript levels are highest.
Feedback mechanisms common to reproduction and
feeding/appetitive/energy homeostasis occur in hypo-
thalamic nuclei. For example, such mechanisms exist
in the paraventricular nuclei with hypophysiotrophic
neurons projecting to the median eminence, and pre-
autonomic neurons controlling autonomic projections to

















the liver(287,293,318,319), arcuate nucleus(283,297), supraoptic
nucleus particularly the TRa(317,320), and adrenal afferents
to the brainstem and suprachiasmatic nucleus via separate
sympathetic and parasympathetic neuron populations(319).
In addition, cross-talk between E2 and thyroid hormones
modulates the activity in the hippocampus and amygdala
contributing to cognition and mood, triggers for emotional
eating in women(282).
Nuclear receptors such as oestrogen receptors and
thyroid hormone receptors bind low-molecular-weight
ligands of E2, selective oestrogen response modulators,
T3 and T4
(278,321), where they co-activate and co-
repress transcription factors at targeted genomic
regions(286,304,305,321–323). However, E2 and thyroid
hormones also bind to plasma membrane receptor sites
initiating non-genomic, ion and intracellular Ca2þ chan-
nels, and G-protein-coupled secondary messenger
cascades discussed above(177,281,282,309,310,324). Future
investigation into the regulation of metabolic homeostasis
between the central nervous system and peripheral tissue
may incorporate genomic analysis of the superfamily of
nuclear receptors (oestrogen receptors and thyroid
hormone receptors) in concert with the neuromodulatory
factors outlined above.
Conclusion
The goal of the present review was to highlight the role of
the complex hormonal interplay in the regulation of food
intake and energy homeostasis. The hormones discussed
in the present review are crucial in the regulation of food
intake and energy homeostasis in that they play the most
significant roles in the function of relevant central, mostly
hypothalamic, circuits. However, they also act as the per-
ipheral signals/mediators of peripheral tissues to inform
hypothalamic circuits of the real-time status of the body’s
constituent energy level. Thus, it appears that ghrelin,
leptin, thyroid hormones, insulin and E2 form a ‘second
zone’ in the modulation of energy homeostasis (Fig. 1).
This second zone lies between the central ‘hotspot’ of
hypothalamic circuits and the peripheral tissues. The per-
ipheral tissues, as appears from our review, represent a
third, ‘outer ring/zone’ in this respect, where local inter-
actions take place between the discussed hormones, on
the one hand, and between the respective tissues and the
trophic hormones, on the other hand. The apparent integ-
rity of the discussed regulatory mechanisms suggests that
the interpretation of hormonal effects alone or in simple
combinations is not sufficient to understand their true
nature, as both individual (feedback signals) and combined
effects are necessary in the complex orchestration of
energy homeostasis, including the regulation of food
intake and energy expenditure. In other words, it seems
most likely that the discussed hormones act as feedback
signals, functioning as individual hormone signals, while
their interactive effects propel and shape the bidirectional
message between the central nervous system and the
periphery. Our summary, therefore, points to the need
for studies involving thorough, multifactorial investigation
of the topic, including the analysis of simultaneous
changes in the aforementioned variables from the central
nervous system, as well as peripheral tissues of the exper-
imental subjects.
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